FDA Approves a Once-Daily Zilbrysq Autoinjector for Generalized Myasthenia Gravis. The Boxed Warning Stays.
UCB's Oct. 16 announcement adds a self-injection device for zilucoplan, with complete dose delivery in 99.8 percent of 449 uses in a 31-patient study. Meningococcal vaccination and REMS enrollment still apply, and launch is expected in early 2027.
On Oct. 16, UCB announced that the Food and Drug Administration approved a once-daily autoinjector for zilucoplan (Zilbrysq) in adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive. The drug, a subcutaneous complement C5 inhibitor, has been approved since 2023. This is a new delivery device, not a new indication.
The autoinjector delivers a preset dose automatically when activated against the skin and becomes a second self-administration option alongside the prefilled syringe. UCB expects it to be commercially available in the US in the first quarter of 2027.
What supported the approval
The filing rested on device studies rather than a new efficacy trial. According to UCB, DV0012 was a phase 1, open-label, single-center, two-period crossover study in 14 healthy volunteers that established bioequivalence between the autoinjector and the syringe. DV0013 was a phase 3b, open-label, multicenter study in 31 adults with generalized myasthenia gravis who self-administered by autoinjector once daily. Complete dose delivery occurred in 99.8 percent of 449 autoinjector uses, and injection-site pain, reported by three patients (9.7 percent), was the most common treatment-emergent adverse event.
A human factors validation study of 100 participants, including patients, caregivers and health care professionals, found that 90 percent completed an injection on the first attempt without training, UCB said. NeurologyLive reported the same figures. Donatello Crocetta, UCB's chief medical officer, said in the announcement that "it was essential to confirm that this added administrative option didn't come at the expense of safety and efficacy."
This approval changes how a patient injects, not who should be treated or what the drug does.
The efficacy data have not changed
Efficacy still rests on the original 12-week, randomized, double-blind, placebo-controlled trial described in the prescribing information, which enrolled 174 patients. The mean change in MG-ADL total score at week 12 was -4.39 with zilucoplan and -2.30 with placebo, a difference of -2.09 (95% CI, -3.24 to -0.95; P<.001). The QMG difference was -2.94 (95% CI, -4.39 to -1.49). Dosing is weight-based: 16.6 mg for patients under 56 kg, 23 mg for 56 to under 77 kg and 32.4 mg for 77 kg and above. The current label lists only the prefilled syringes.
The label warnings stay
Zilucoplan carries a boxed warning for serious meningococcal infections, which can be rapidly life-threatening or fatal, and is available only through the Zilbrysq Risk Evaluation and Mitigation Strategy program. Meningococcal vaccination should be completed or updated at least two weeks before the first dose unless delaying therapy outweighs the infection risk, and vaccination does not eliminate the risk. The label also warns of pancreatitis and pancreatic cysts, with baseline lipase and amylase recommended. Injection-site reactions (29 percent versus 16 percent with placebo), upper respiratory infections and diarrhea were the most common adverse reactions in the pivotal trial.
The device studies were small and open-label, with no comparator for the self-injection data, and the device results come from the company's announcement rather than a peer-reviewed publication.
What it means in clinic
For neurologists with patients already on the syringe, the practical questions are access and training: whether pharmacy and REMS arrangements carry over to the new device, who teaches the first injection, and how vaccination status is confirmed over time. Nothing changes before 2027, so there is no switch to arrange this week. For broader context on rare disease regulation, see our piece on FDA's rare disease framework.
Reported, fact-checked and edited by The Script Pad's editorial staff.
This article is for professional education and does not replace clinical judgment. Treatment decisions should be based on the individual patient and current guidelines.
